Key result
Phosphodiesterase III inhibitors such as milrinone may exert less metabolic stress and cause less renal impairment compared to adrenaline in patients with low cardiac output after cardiac surgery.
Why the study?
Do phosphodiesterase III inhibitors improve energy metabolism and visceral organ function compared to catecholamines in patients with low cardiac output or severe left heart failure associated with cardiac surgery?
Do phosphodiesterase III inhibitors improve energy metabolism and visceral organ function compared to catecholamines in patients with low cardiac output or severe left heart failure associated with cardiac surgery?
This article highlights the need to study the metabolic and visceral organ effects of phosphodiesterase III inhibitors compared to catecholamines in cardiac surgery patients.
Phosphodiesterase III inhibitors combine positive inotropic and vasodilator properties. These inhibitors are therefore frequently used to treat low cardiac output and/or severe left heart failure associated with cardiac surgery. Their effects on energy metabolism and visceral organ function are not well studied, however, particularly in comparison with their 'competitors' in daily practice (that is, catecholamines).
No takes yet. Share an insight, caveat, or question.
Šimková et al. (2007) conducted an editorial in Low cardiac output after coronary artery bypass surgery. Milrinone vs. Adrenaline was evaluated. Phosphodiesterase III inhibitors such as milrinone may exert less metabolic stress and cause less renal impairment compared to adrenaline in patients with low cardiac output after cardiac surgery.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: